Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC).

Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPKIRSCHBROWN, Whitney PaigeWANG, BeiNIJEM, IhsanOHTSU, AtsushiHOFF, Paulo M.SHAH, Manish A.2019-01-292019-01-292018JOURNAL OF CLINICAL ONCOLOGY, v.36, n.15, suppl.S, 20180732-183Xhttps://observatorio.fm.usp.br/handle/OPI/30453engrestrictedAccessPharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC).conferenceObjectCopyright AMER SOC CLINICAL ONCOLOGY10.1200/JCO.2018.36.15_suppl.2564Oncology1527-7755